A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Activated protein C (APC) exerts anticoagulant and cytoprotective cell signaling activities. APC's cell signaling requires protease-activated receptor (PAR) PAR1 and PAR3, and APC's PAR cleavages generate peptides capable of agonizing biased G-protei…
INTRODUCTION: Injectable formulations are common for protein-based therapeutics. However, non-injectable formulations are crucial for improving patient compliance. This study aims to develop hyaluronic acid/aminoclay-based dissolving microneedles as…
OBJECTIVE: The objective of this pilot study is to evaluate the feasibility of using an automatic weight management system to follow patients' response to weight reduction medications and to identify early deviations from weight trajectories. METHODS…
BACKGROUND: Semaglutide is an effective antidiabetic agent that is injected weekly to induce weight reduction, and the impact on cardiovascular outcomes is favorable. OBJECTIVE: The aim was to evaluate the persistence of the use of weekly injectable…
Semaglutide is a lipopeptide with important applications in the treatment of diabetes, obesity, and other conditions. This class of drug (glucagon-like peptide-1 agonists and other lipidated peptides) may be susceptible to aggregation due to the tend…
BACKGROUND: CKD is a significant public health issue, affecting approximately half a billion people globally. Key risk factors for CKD include obesity, hypertension, cardiovascular diseases and diabetes. Glucagon-like peptide-1 receptor agonists (GLP…
BACKGROUND: Overweight and obesity have a negative impact on health and have a detrimental effect on the operational readiness of soldiers. Different prevention and intervention measures against obesity include diet, physical activity, education, coa…
The use of the GLP-1R agonist semaglutide is revolutionizing the treatment of obesity, yet its mechanistic effects on energy balance remain elusive. Here, we demonstrate that reactivation of semaglutide-responsive dorsal vagal complex neurons mimics…
Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a promising pharmacological intervention in obesity management. This systematic review aimed to evaluate the efficacy and safety of semaglutide in promoting weight loss in adults…
: Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by insulin resistance, impaired insulin secretion, and chronic hyperglycemia. Recent studies have identified microRNAs (miRNAs), a class of small non-coding RNAs that reg…
INTRODUCTION: This systematic review and meta‑analysis is the first to comprehensively compare oral and subcutaneous semaglutide for type 2 diabetes (T2D) management. OBJECTIVES: Our aim was to determine whether oral semaglutide is noninferior to the…
BACKGROUND: Alcohol use disorder (AUD) is a major global health burden with high relapse rates and limited treatment uptake. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), developed for type 2 diabetes and obesity, may also reduce alcohol con…
PURPOSE: This study used artificial intelligence (AI) and natural language processing (NLP) to analyze patient reviews of semaglutide, with the goal of better understanding its real-world effectiveness and safety for weight management. METHODS: A ret…
Obesity is a global health concern with new medication treatment options. So far, research on how programs with newer anti-obesity medication (AOM) for the moderate- to high-risk population can mitigate the prevalence of obesity and reduce the econom…
Background Glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, along with GLP-1R monoagonist, show promise in treating metabolic dysfunction-associated steatotic liver disease (MASLD). Liver fat and iron content are i…
BACKGROUND: Type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) frequently coexist, posing a significant challenge due to increased risks of cardiovascular disease and mortality. Glucagon-like peptide-1 receptor agonists, such as semaglu…
The gut microbiota plays a crucial role in the human body and has an impact on the physiological function of the host. In particular, changes in the gut microbiota are especially pronounced in patients with type 2 diabetes. There is ample evidence th…
Excessive caloric intake, particularly dietary triglycerides contributes to the development of obesity. Monoacylglycerol acyltransferase 2 (hMOGAT2/mMgat2) plays a crucial role in their resynthesis for their transport to the liver. The human MOGAT2 i…